BRPI0406996A - Formas de dosagem sólida via transmucosa oral sem açúcar e sua utilização - Google Patents

Formas de dosagem sólida via transmucosa oral sem açúcar e sua utilização

Info

Publication number
BRPI0406996A
BRPI0406996A BR0406996-0A BRPI0406996A BRPI0406996A BR PI0406996 A BRPI0406996 A BR PI0406996A BR PI0406996 A BRPI0406996 A BR PI0406996A BR PI0406996 A BRPI0406996 A BR PI0406996A
Authority
BR
Brazil
Prior art keywords
dosage forms
sugar
solid dosage
oral solid
transmucosal dosage
Prior art date
Application number
BR0406996-0A
Other languages
English (en)
Inventor
Brian Hague
Lynn J Maland
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of BRPI0406996A publication Critical patent/BRPI0406996A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMAS DE DOSAGEM SóLIDA VIA TRANSMUCOSA ORAL SEM AçúCAR E SUA UTILIZAçãO". A presente invenção é destinada às formas de dosagem sólida por via oral. As formas de dosagem sólida são sem açúcar e consistem em um agente farmacêutico e em um excipiente aceitável farmaceuticamente. Preferencialmente, as formas de dosagem sólida da presente invenção são bioequivalentes a uma forma de dosagem sólida contendo açúcar. A bioequivalência é preferencialmente obtida pela incorporação de um agente ionizante, mais preferencialmente na forma de um sistema de tampão, nas formas de dosagem sólida, em uma quantidade suficiente para manter uma parte do agente farmacêutico, após a dissolução da composição citada na saliva, em um estado ionizado.
BR0406996-0A 2003-02-04 2004-02-04 Formas de dosagem sólida via transmucosa oral sem açúcar e sua utilização BRPI0406996A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44483203P 2003-02-04 2003-02-04
US10/771,046 US20040253307A1 (en) 2003-02-04 2004-02-03 Sugar-free oral transmucosal solid dosage forms and uses thereof
PCT/US2004/003055 WO2004069198A2 (en) 2003-02-04 2004-02-04 Sugar-free oral transmucosal solid dosage forms and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0406996A true BRPI0406996A (pt) 2006-01-10

Family

ID=32853394

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406996-0A BRPI0406996A (pt) 2003-02-04 2004-02-04 Formas de dosagem sólida via transmucosa oral sem açúcar e sua utilização

Country Status (11)

Country Link
US (1) US20040253307A1 (pt)
EP (1) EP1596836A2 (pt)
JP (1) JP2006516648A (pt)
KR (1) KR20050105198A (pt)
AU (1) AU2004208827A1 (pt)
BR (1) BRPI0406996A (pt)
CA (1) CA2515025A1 (pt)
IL (1) IL169902A0 (pt)
MX (1) MXPA05008278A (pt)
TW (1) TW200505498A (pt)
WO (1) WO2004069198A2 (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0302017B1 (pt) * 2003-06-02 2014-10-29 Ems Sigma Pharma Ltda Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos
US20060004035A1 (en) * 2004-06-25 2006-01-05 Cephalon, Inc. System for identification of a pharmaceutical product
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
EP2522365B1 (en) 2004-11-24 2016-10-26 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
PE20061245A1 (es) * 2005-03-30 2007-01-06 Generex Pharm Inc Composiciones para la transmision transmucosa oral de la metformina
CA2603402C (en) * 2005-04-08 2017-10-31 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
US20070020186A1 (en) * 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
JP4991134B2 (ja) * 2005-09-15 2012-08-01 ルネサスエレクトロニクス株式会社 半導体装置およびその製造方法
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US9289583B2 (en) * 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
WO2007089652A2 (en) * 2006-01-27 2007-08-09 Cadbury Adams Usa Llc Flavor-enhancing compositions, methods of manufacture, and methods of use
JP5410964B2 (ja) * 2006-05-23 2014-02-05 オラヘルス コーポレーション 付着性アカシアゴムを含む二層構造の口腔内付着錠
AR058431A1 (es) * 2006-07-12 2008-02-06 Karen Elizabeth Quiroga Procedimiento para la fabricacion de analgesicos a base de fentanilo para su administracion por via oral transmucosa bajo forma de caramelo
SI2054031T1 (sl) 2006-07-21 2016-09-30 Biodelivery Sciences International, Inc. Transmukozne naprave za administracijo z izboljšanim vnosom
DE102006044694A1 (de) * 2006-09-22 2008-03-27 Krewel Meuselbach Gmbh Perorale feste Schmerzmittelzubereitung
CN101621994B (zh) * 2007-01-05 2016-06-01 阿塞尔Rx制药有限公司 用于治疗疼痛的含舒芬太尼的小量口腔跨粘膜剂型
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
JP2010534660A (ja) * 2007-07-23 2010-11-11 テイコク ファーマ ユーエスエー インコーポレーテッド 官能的に許容されるインドールセロトニン受容体アゴニスト経口投与剤および該剤を用いる方法
WO2009026434A1 (en) * 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
US8143222B2 (en) * 2007-10-22 2012-03-27 Washington University Modular platform for targeted therapeutic delivery
DE102008003658A1 (de) * 2008-01-09 2009-07-16 Emitec Gesellschaft Für Emissionstechnologie Mbh Wabenkörper mit strukturiertem Blechmaterial
US20090263476A1 (en) * 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
WO2010107761A1 (en) 2009-03-18 2010-09-23 Acelrx Pharmaceuticals, Inc. Improved storage and dispensing devices for administration of oral transmucosal dosage forms
EP2435052B1 (en) * 2009-05-27 2015-07-15 Hetero Research Foundation Solid oral dosage forms of lamivudine with isomalt
EP2453916A4 (en) * 2009-07-17 2013-06-05 Univ Oklahoma State SUPRALINGUAL VACCINES AND APPLICATORS
US12016950B2 (en) 2010-09-01 2024-06-25 Try This First, Inc. Devices and methods for treating ear pain
US10080718B2 (en) 2010-09-01 2018-09-25 Try This First, Inc. Method of treating ear infections
US8604078B2 (en) * 2011-04-06 2013-12-10 Carlos Picornell Darder Fosfomycin pharmaceutical composition
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
CN104136010A (zh) * 2012-02-19 2014-11-05 奥拉黑尔斯公司 用于口腔粘附圆片的碱化金合欢树胶粘合剂
US9044035B2 (en) 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
US20150030685A1 (en) * 2013-07-23 2015-01-29 Lynn J. Maland Sugar-Free Oral Transmucosal Fentanyl Citrate Lozenge Dosage Forms
US10105320B2 (en) 2013-10-03 2018-10-23 Altria Client Services Soluble fiber lozenge
US9375033B2 (en) 2014-02-14 2016-06-28 R.J. Reynolds Tobacco Company Tobacco-containing gel composition
US20150335572A1 (en) * 2014-05-26 2015-11-26 Michael Lee Martin Medicated Hard Candy Product For Treating Esophageal Inflammation And A Method Using The Same
US11135158B2 (en) 2014-05-26 2021-10-05 Michael Lee Martin Medicated hard candy product for treating esophageal inflammation and a method using the same
WO2016106329A1 (en) 2014-12-23 2016-06-30 Acelrx Pharmaceuticals, Inc. Systems, devices and methods for dispensing oral transmucosal dosage forms
EP3368097B1 (en) 2015-10-30 2020-03-18 AcelRx Pharmaceuticals, Inc. Apparatus and methods for dispensing oral transmucosal dosage forms
JP2023553204A (ja) * 2020-12-06 2023-12-20 トランスダーマル セデーション ソリューション，エルエルシー 歯科処置における鎮静のためのクロニジン及びミダゾラムの経口製剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863737A (en) * 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5132114A (en) * 1985-05-01 1992-07-21 University Of Utah Research Foundation Compositions and methods of manufacture of compressed powder medicaments
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US4971798A (en) * 1989-11-30 1990-11-20 Miles Inc. Hard confections containing hydrogenated isomaltulose and medicinally active ingredient
RO113611B1 (ro) * 1990-08-03 1998-09-30 Asta Pharma Ag Preparate solide de ifosfamida, administrate oral si procedeu de obtinere
FR2705207B1 (fr) * 1993-05-17 1995-07-28 Roquette Freres Procédé de dragéification dure sans sucre et produits ainsi obtenus.
FR2728436A1 (fr) * 1994-12-26 1996-06-28 Roquette Freres Sucre cuit et son procede de fabrication
US6680071B1 (en) * 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
US6210699B1 (en) * 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
AU3221401A (en) * 1999-11-30 2001-06-12 Rajesh Jain Fast dissolving composition with prolonged sweet taste
DE10013712A1 (de) * 2000-03-20 2001-09-27 Nutrinova Gmbh Nikotinsalze mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung
JP3909998B2 (ja) * 2000-03-22 2007-04-25 田辺製薬株式会社 経口投与製剤
AU2001261744A1 (en) * 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
US6555581B1 (en) * 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20020160043A1 (en) * 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
CN101301275A (zh) * 2001-03-26 2008-11-12 史密丝克莱恩比彻姆公司 含烟碱的口服剂量形式的制备方法

Also Published As

Publication number Publication date
JP2006516648A (ja) 2006-07-06
CA2515025A1 (en) 2004-08-19
EP1596836A2 (en) 2005-11-23
IL169902A0 (en) 2007-07-04
TW200505498A (en) 2005-02-16
WO2004069198A2 (en) 2004-08-19
MXPA05008278A (es) 2006-05-31
AU2004208827A1 (en) 2004-08-19
US20040253307A1 (en) 2004-12-16
WO2004069198A3 (en) 2004-10-07
KR20050105198A (ko) 2005-11-03

Similar Documents

Publication Publication Date Title
BRPI0406996A (pt) Formas de dosagem sólida via transmucosa oral sem açúcar e sua utilização
ES2187822T3 (es) Comprimidos de disgregacion rapida.
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
UY30537A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
AR012358A1 (es) Formulaciones de liberacion prolongada de derivados de eritromicina y su uso para la manufactura de un medicamento
BR0009437A (pt) Amido pré-gelatinizado em uma formulação de liberação controlada
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
AR036768A1 (es) Formas de administracion de propiverina o sus sales farmaceuticamente aceptables con liberacion prolongada de la sustancia activa
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
PT833618E (pt) Forma farmaceutica solida para utilizacao oral
NO20084065L (no) Hurtig frigivelses paracetamol tabletter
PT1131050E (pt) Formulacoes galenicas que se desintegram rapidamente na boca e metodo para as preparar
NO20030897D0 (no) Fremgangsmåte for fremstilling av farmasöytiske sammensetninger for anvendelse med blöte gelatin formuleringer
BRPI0513455A (pt) formulação para mascaramento de sabor compreendendo o fármaco em uma forma de dissolução retardada e/ou ciclodextrina em uma forma de dissolução melhorada
WO2002024203A3 (en) Controlled release formulations for oral administration
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
BR0312728A (pt) Formulação em tablete dispersìvel e processo para sua preparação
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
BRPI0418275A (pt) formulações em multipartìculas para distribuição oral
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
ATE460156T1 (de) Puffende orale darreichungsformen
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
BR0112847A (pt) Uso de uma forma de dosagem sólida
AR001765A1 (es) Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]